Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. The day's gain was powered by the telehealth company's ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...

(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its ...

The Good Bug’s formulation, priced at Rs 2,000 per month, is based on microbiome research. A randomised, double-blinded, ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...